Precipio (NASDAQ:PRPO) Issues Quarterly Earnings Results

Precipio (NASDAQ:PRPO) announced its earnings results on Thursday. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, FiscalAI reports. Precipio had a negative net margin of 1.51% and a negative return on equity of 2.78%. The business had revenue of $6.71 million for the quarter.

Precipio Stock Performance

Precipio stock traded down $1.90 during midday trading on Friday, hitting $26.70. The stock had a trading volume of 1,966 shares, compared to its average volume of 23,485. The firm’s fifty day moving average is $27.86 and its two-hundred day moving average is $24.84. The company has a market capitalization of $47.52 million, a PE ratio of -106.96 and a beta of 1.38. Precipio has a 52-week low of $7.31 and a 52-week high of $33.63. The company has a current ratio of 1.61, a quick ratio of 1.36 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On Precipio

A number of hedge funds have recently modified their holdings of PRPO. Susquehanna International Group LLP purchased a new stake in shares of Precipio in the third quarter worth $194,000. Renaissance Technologies LLC lifted its stake in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares in the last quarter. Evernest Financial Advisors LLC bought a new position in Precipio in the 3rd quarter worth $374,000. Finally, Topline Capital Management LLC bought a new position in Precipio in the 3rd quarter worth $1,158,000. 10.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PRPO has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. Wall Street Zen raised Precipio from a “hold” rating to a “buy” rating in a report on Saturday, April 4th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Precipio presently has a consensus rating of “Sell”.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.